stockrow
Friday 6 November 2026
Export BIO.B’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
379.50
15.35
+4.22%
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Net income
Over the twelve months to 30 June 2026 it was $616.6M. Bio-Rad Laboratories, Inc. ranks 12th of 149 Medical Devices companies by net income.
Net income, annual
Annual newest first
| Period | Net income | Change |
|---|
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $371.4M | — |
| Sep 2025 | −$341.9M | — |
| Jun 2025 | $317.8M | 18.01% |
| Sep 2018 | $269.3M | 0.47% |
| 14 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| BIO.B Bio-Rad Laboratories, Inc. | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| GMED Globus Medical, Inc. compare | $557.6M |
| PODD Insulet Corporation compare | $428.8M |
| PEN Penumbra, Inc. compare | $157.0M |
| TXG 10x Genomics compare | −$75.1M |
| BRKR Bruker Corporation compare | −$115.7M |
| GKOS Glaukos Corporation compare | −$169.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BIO.B
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement